Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
A lean first quarter for venture-backed developers
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Corporate venture investors stay strong
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
The bubble bursts for biotech stocks
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
EQRX aims for biopharma Spac record
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.